Imperial College London
Portrait Picture

Professor Justin Roe

Faculty of Medicine, Department of Surgery & Cancer

Professor of Practice (Speech and Swallowing Rehabilitation)
 
 
 
//

Contact

 

justin.roe

 
 
//

Location

 

Charing Cross HospitalCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Petkar:2016:10.1186/s12885-016-2813-0,
author = {Petkar, I and Rooney, K and Roe, JWG and Patterson, JM and Bernstein, D and Tyler, JM and Emson, MA and Morden, JP and Mertens, K and Miles, E and Beasley, M and Roques, T and Bhide, SA and Newbold, KL and Harringtonl, KJ and Hall, E and Nutting, CM},
doi = {10.1186/s12885-016-2813-0},
journal = {BMC Cancer},
title = {DARS: a phase III randomised multicentre study of dysphagia- optimised intensity-modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer},
url = {http://dx.doi.org/10.1186/s12885-016-2813-0},
volume = {16},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundPersistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients’ quality of life. Single arm studies have shown that the dosimetric sparing of critical swallowing structures such as the pharyngeal constrictor muscle and supraglottic larynx can translate to better functional outcomes. However, there are no current randomised studies to confirm the benefits of such swallow sparing strategies. The aim of Dysphagia/Aspiration at risk structures (DARS) trial is to determine whether reducing the dose to the pharyngeal constrictors with dysphagia-optimised intensity- modulated radiotherapy (Do-IMRT) will lead to an improvement in long- term swallowing function without having any detrimental impact on disease-specific survival outcomes.Methods/designThe DARS trial (CRUK/14/014) is a phase III multicentre randomised controlled trial (RCT) for patients undergoing primary (chemo) radiotherapy for T1-4, N0-3, M0 pharyngeal cancers. Patients will be randomised (1:1 ratio) to either standard IMRT (S-IMRT) or Do-IMRT. Radiotherapy doses will be the same in both groups; however in patients allocated to Do-IMRT, irradiation of the pharyngeal musculature will be reduced by delivering IMRT identifying the pharyngeal muscles as organs at risk. The primary endpoint of the trial is the difference in the mean MD Anderson Dysphagia Inventory (MDADI) composite score, a patient-reported outcome, measured at 12 months post radiotherapy. Secondary endpoints include prospective and longitudinal evaluation of swallow outcomes incorporating a range of subjective and objective assessments, quality of life measures, loco-regional control and overall survival. Patients and speech and language therapists (SLTs) will both be blinded to treatment allocation arm to minimise outcome-reporting bias.DiscussionDARS is the first RCT investigating the effect of swallow sparing strategies on improving long-term swallowing outcomes
AU  - Petkar,I
AU  - Rooney,K
AU  - Roe,JWG
AU  - Patterson,JM
AU  - Bernstein,D
AU  - Tyler,JM
AU  - Emson,MA
AU  - Morden,JP
AU  - Mertens,K
AU  - Miles,E
AU  - Beasley,M
AU  - Roques,T
AU  - Bhide,SA
AU  - Newbold,KL
AU  - Harringtonl,KJ
AU  - Hall,E
AU  - Nutting,CM
DO  - 10.1186/s12885-016-2813-0
PY  - 2016///
SN  - 1471-2407
TI  - DARS: a phase III randomised multicentre study of dysphagia- optimised intensity-modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer
T2  - BMC Cancer
UR  - http://dx.doi.org/10.1186/s12885-016-2813-0
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000442572400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2813-0
UR  - http://hdl.handle.net/10044/1/76983
VL  - 16
ER  -
Download